These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 34517768)

  • 1. Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities.
    de Havenon A; Sheth KN; Madsen TE; Johnston KC; Turan TN; Toyoda K; Elm JJ; Wardlaw JM; Johnston SC; Williams OA; Shoamanesh A; Lansberg MG
    Stroke; 2021 Oct; 52(10):e635-e645. PubMed ID: 34517768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    Toyoda K; Uchiyama S; Hoshino H; Kimura K; Origasa H; Naritomi H; Minematsu K; Yamaguchi T;
    Int J Stroke; 2015 Feb; 10(2):253-8. PubMed ID: 25487817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial.
    Hoshino H; Toyoda K; Omae K; Ishida N; Uchiyama S; Kimura K; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K; Matsumoto M; Tominaga T; Tomimoto H; Terayama Y; Yasuda S; Yamaguchi T;
    Stroke; 2021 Nov; 52(11):3430-3439. PubMed ID: 34404237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
    Nishiyama Y; Kimura K; Otsuka T; Toyoda K; Uchiyama S; Hoshino H; Sakai N; Okada Y; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Minematsu K; Matsumoto M; Tominaga T; Tomimoto H; Terayama Y; Yasuda S; Yamaguchi T;
    Stroke; 2023 Mar; 54(3):697-705. PubMed ID: 36734235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
    Manolis AA; Manolis TA; Melita H; Mikhailidis DP; Manolis AS
    J Clin Pharmacol; 2022 Mar; 62(3):320-358. PubMed ID: 34671983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
    Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K;
    Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis.
    Toyoda K; Omae K; Hoshino H; Uchiyama S; Kimura K; Miwa K; Minematsu K; Yamaguchi K; Suda Y; Toru S; Kitagawa K; Ihara M; Koga M; Yamaguchi T;
    Neurology; 2022 Mar; 98(10):e983-e992. PubMed ID: 35074890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
    Uchiyama S; Toyoda K; Okamura S; Omae K; Hoshino H; Kimura K; Kitagawa K; Minematsu K; Yamaguchi T
    Int J Stroke; 2023 Apr; 18(4):426-432. PubMed ID: 35762581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol for treatment of cerebral infarction.
    Noma K; Higashi Y
    Expert Opin Pharmacother; 2018 Oct; 19(15):1719-1726. PubMed ID: 30212227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
    McHutchison C; Blair GW; Appleton JP; Chappell FM; Doubal F; Bath PM; Wardlaw JM
    Stroke; 2020 Aug; 51(8):2374-2385. PubMed ID: 32646330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure during long-term cilostazol-based dual antiplatelet therapy after stroke: a post hoc analysis of the CSPS.com trial.
    Toyoda K; Koga M; Tanaka K; Uchiyama S; Sunami H; Omae K; Kimura K; Hoshino H; Fukuda-Doi M; Miwa K; Koge J; Okada Y; Sakai N; Minematsu K; Yamaguchi T;
    Hypertens Res; 2024 Sep; 47(9):2238-2249. PubMed ID: 38977876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
    Lin MP; Meschia JF; Gopal N; Barrett KM; Ross OA; Ertekin-Taner N; Brott TG
    J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105581. PubMed ID: 33388632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
    Lee YJ; Je NK
    Eur J Clin Pharmacol; 2023 Aug; 79(8):1107-1116. PubMed ID: 37310478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke.
    Zhou LW; Kraler L; de Havenon A; Lansberg MG
    J Am Heart Assoc; 2022 Jun; 11(11):e024992. PubMed ID: 35656996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
    Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
    BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com.
    Hoshino H; Toyoda K; Omae K; Takahashi K; Uchiyama S; Kimura K; Yamaguchi K; Minematsu K; Origasa H; Yamaguchi T
    J Atheroscler Thromb; 2023 Jun; 30(6):675-683. PubMed ID: 36070920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
    Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
    Shah J; Liu S; Yu W
    Stroke Vasc Neurol; 2022 Oct; 7(5):406-414. PubMed ID: 35393359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of cilostazol for secondary stroke prevention: an old dog with new tricks?
    Ansara AJ; Shiltz DL; Slavens JB
    Ann Pharmacother; 2012 Mar; 46(3):394-402. PubMed ID: 22353234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
    Kamal AK; Naqvi I; Husain MR; Khealani BA
    Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD008076. PubMed ID: 21249700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.